Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes by 媛뺤��꽍 et al.
ORIGINAL RESEARCH
published: 23 November 2018
doi: 10.3389/fendo.2018.00691
Frontiers in Endocrinology | www.frontiersin.org 1 November 2018 | Volume 9 | Article 691
Edited by:
Tarunveer Singh Ahluwalia,
Steno Diabetes Center Copenhagen
(SDCC), Denmark
Reviewed by:
Eusebio Chiefari,
Dipartimento di Scienze della Salute,
Università degli Studi Magna Graecia
di Catanzaro, Italy
Daniela Patrizia Foti,
Università degli studi Magna Græcia di
Catanzaro, Italy
*Correspondence:
Sang-Guk Lee
comforter6@yuhs.ac
Yong-ho Lee
yholee@yuhs.ac
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Genomic Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 28 June 2018
Accepted: 02 November 2018
Published: 23 November 2018
Citation:
Yim J, Kim G, Lee B-W, Kang ES,
Cha B-S, Kim J-H, Cho JW, Lee S-G
and Lee Y-h (2018) Relationship
Between Circulating Netrin-1
Concentration, Impaired Fasting
Glucose, and Newly Diagnosed Type
2 Diabetes. Front. Endocrinol. 9:691.
doi: 10.3389/fendo.2018.00691
Relationship Between Circulating
Netrin-1 Concentration, Impaired
Fasting Glucose, and Newly
Diagnosed Type 2 Diabetes
Jisook Yim 1,2,3†, Gyuri Kim 4†, Byung-Wan Lee 5,6, Eun Seok Kang 5,6, Bong-Soo Cha 5,6,
Jeong-Ho Kim 1, Jin Won Cho 7, Sang-Guk Lee 1* and Yong-ho Lee 5,6,7*
1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, South Korea, 2Division of Special
Chemistry, Green Cross Reference Laboratory, Yongin-si, South Korea, 3Department of Laboratory Medicine, Veterans
General Hospital, Incheon, South Korea, 4Division of Endocrinology and Metabolism, Department of Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5Department of Internal Medicine, Yonsei
University College of Medicine, Seoul, South Korea, 6 Institute of Endocrine Research, Yonsei University College of Medicine,
Seoul, South Korea, 7Department of Systems Biology, Glycosylation Network Research Center, Yonsei University, Seoul,
South Korea
Background: The protein netrin-1 has demonstrated anti-inflammatory, tissue
regeneration, and immune modulation properties. Although inflammation is a major
contributing factor in the development of insulin resistance and type 2 diabetes, little
is known about a possible relationship between serum netrin-1 and type 2 diabetes.
Therefore, we investigated the association between circulating levels of netrin-1 and
glycometabolic parameters predictive of type 2 diabetes.
Methods: Serum samples were collected from 41 normal controls, 85 subjects with
impaired fasting glucose (IFG), and 92 subjects with newly diagnosed type 2 diabetes.
Clinical and laboratory parameters were assessed and netrin-1 levels were measured by
commercial enzyme-linked immunosorbent assay. Spearman correlation analyses and
multivariable-adjusted regression analyses were conducted to examine the relationship
between serum netrin-1 levels and glycometabolic parameters.
Results: Serum netrin-1 levels in subjects with type 2 diabetes or IFG were significantly
higher compared to normal controls (441.0, 436.6, and 275.9 pg/mL, respectively; P for
trend <0.001). Serum netrin-1 levels were significantly positively correlated with fasting
glucose, HbA1c, and insulin resistance index (all Ps < 0.01). Serum netrin-1 levels
were independently associated with IFG or type 2 diabetes (standardized β = 0.405,
P < 0.001) after adjusting for covariates and potential confounders. In addition, the
receiver operating characteristic (ROC) analysis showed that serum netrin-1 levels could
identify the presence of IFG and type 2 diabetes with the area under the ROC curve
(AUC) of 0.784 (P < 0.001).
Conclusions: Our results suggest that elevated serum netrin-1 levels are significantly
associated with the presence of IFG and type 2 diabetes.
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BACKGROUND
As incidence rates of obesity and insulin resistance increases
worldwide, the prevalence of diabetes continues to rise
dramatically (1). The global population of type 2 diabetesmellitus
is expected to grow to more than 366 million people by 2030,
from 171 million in 2000 (2). Acute and chronic complications of
diabetes and its associated highmorbidity produce overwhelming
burdens on healthcare systems and society (3). In addition to
patients with diabetes, people with impaired fasting glucose
(IFG) account for increasing socioeconomic costs associated
with substantially increased risks of vascular disease and overall
mortality (4, 5). Moreover, undiagnosed diabetes in young people
is associated with an increased risk of cardiovascular disease
(6, 7). Early diagnosis and management of type 2 diabetes is of
critical importance and should be emphasized due to the often
silent symptoms of its progression. Thus, reliable biomarkers to
identify IFG or type 2 diabetes are needed.
Netrin-1, which belongs to a family of laminin-related
proteins, has been reported as a neuronal guidance cue, acting
as both a chemo-attractant and as a chemo-repulsive force
during axonal migration (8, 9). Netrin-1 is primarily expressed
in the central nervous system (CNS), but also in non-neural
tissues such as vascular endothelial cells, pancreas, liver, spleen,
lung, intestine, and kidney (10). In recent studies, netrin-1 was
shown to play various other key roles beyond axonal guidance
during nervous system development, including organogenesis
of mammary glands, lungs, and pancreas, and angiogenesis
and tumorigenesis (11–13). In addition, netrin-1 was reported
to be involved in leukocyte migration in peripheral organs,
in tissue regeneration, and in modulation of inflammation-
based conditions (10, 14–18). Moreover, netrin-1 exhibited an
anti-angiogenic effect, allowing an improvement in blood flow
to hypoxic tissue, and showed a promising cardioprotective
capacity in the prevention of ischemia-reperfusion injury by
consequent nitric oxide production in animal studies (19–
22). Inflammation is a major contributor to the development
of diabetes (23). Increased oxidative stress and various pro-
inflammatory cytokines and chemokines, including tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which
might interfere with anti-inflammatory effects on insulin action,
were associated with insulin resistance, obesity, and type 2
diabetes (23, 24). Moreover, there is evidence to suggest that
prior to its onset, diabetes displays features of inflammation
(25). This notion, coupled with the tissue regenerative and
immunomodulatory properties of netrin-1, led us to explore
whether circulating levels might be related to the development
of IFG or type 2 diabetes. Therefore, we investigated circulating
levels of netrin-1 and its associations with clinical parameters in
Abbreviations: A2BAR, adenosine 2B receptor; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; AUC, areas under the receiver operating
characteristic curves; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; COX-2, cyclooxygenase-2; DCC, deleted in colorectal cancer;
IFG, impaired fasting glucose; OD, optical density; PGE2, prostaglandin E2;
PMNs, polymorphonuclear neutrophils; ROC, receiver operating characteristic;
STD, standardized; UNC5, uncoordinated 5; VIF, variance inflation factor.
three population groups: normal controls and individuals with
IFG and type 2 diabetes.
METHODS
Study Population
Participants were individuals who visited the Diabetes Center at
the tertiary-level, university-affiliated Severance Hospital, Seoul,
Korea from September 2015 to January 2017. Subjects with
current renal or hepatic disease, malignancy, diabetes other than
type 2 diabetes mellitus, any acute inflammation or infection,
current significant cardiovascular disease, and those taking
anti-diabetes medication were excluded from participation. We
enrolled the drug-naïve patients with type 2 diabetes and
laboratory parameters were determined at diagnosis, considering
the effect of anti-diabetes drugs on circulating netrin-1 levels.
A total of 218 individuals were enrolled and classified as
normal controls (n = 41), subjects with IFG (n = 85), and
subjects with newly-diagnosed type 2 diabetes (n = 92). Written
informed consent, compatible with the Helsinki Declaration, was
provided by participants prior to enrolling into the study, which
was approved by the Institutional Review Board of Severance
Hospital (IRB No. 4-2015-0503).
Definition of Normal, Impaired Fasting
Glucose, and Type 2 Diabetes
In this study, we defined normal controls as a fasting glucose
level <100 mg/dL and HbA1c <5.7%), IFG as a fasting glucose
level of 100–125 mg/dL or HbA1c of 5.7–6.5% without taking
anti-diabetes medication, and newly diagnosed type 2 diabetes as
a fasting glucose level ≥126 mg/dL or 2-h postprandial glucose
level ≥200 mg/dL or HbA1c ≥6.5% without taking anti-diabetes
medication (26). Levels of postprandial glucose were measured in
17.1% (n= 7), 68.2% (n= 58), and 88.0% (n= 81) in individuals
with normal, IFG, and type 2 diabetes, respectively.
Measurement of Clinical and Laboratory
Parameters
Personal medical history, smoking status, alcohol consumption
habits, and anthropometric data were collected. Subjects
were categorized with regard to smoking status and alcohol
consumption (non-current or current). Body weight and height
were measured, and body mass index (BMI) was calculated as
kg/m2. Obesity was defined according to the criteria for the
Asian and Pacific regions (BMI≥ 25 kg/m2) (27). Blood pressure
was measured by using a mercury sphygmomanometer in a
sitting positing after at least 5min of rest. Participants’ blood
samples were collected after fasting for 8–12 h. Serum samples
were placed into Eppendorf cryotubes and stored at −80◦C
until runtime. HbA1c was determined using the Cobas Integra
800 system (Roche Diagnostics, Germany). Serum glucose, 2-h
postprandial glucose, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), total cholesterol, triglycerides, and
high density lipoprotein (HDL) cholesterol were determined
using a Hitachi 7600 analyzer (Hitachi Co., Tokyo, Japan).
Fasting serum insulin and C-peptide levels were determined
using electrochemiluminescent assay and Cobas e601 analyzer
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(Roche Diagnostics). Low density lipoprotein (LDL) cholesterol
was calculated using the Friedewald equation (LDL cholesterol
[mg/dL] = total cholesterol [mg/dL] – HDL cholesterol [mg/dL]
– triglycerides [mg/dL]/5). Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) was calculated from the following
formula: [fasting plasma insulin (µIU/mL) × fasting plasma
glucose (mg/dL) /405] (28, 29). Estimated glomerular filtration
rate (eGFR) was calculated based on the CKD Epidemiology
Collaboration (CKD-EPI) equation (30). Levels of netrin-1 were
measured by commercial enzyme-linked immunosorbent assay
(ELISA; Cloud-Clone Corp., Houston, TX, USA) according to
the manufacturer’s instructions. Three ELISA kits with same lot
number (No. L170220861) were used. Each ELISA assay included
sera from all the three categories of individuals examined.
Although there was no internal control materials, all tested
ELISA kits were same lot number and the assays were performed
by one researcher on the same day. In addition, the mean
netrin-1 concentration of each category of individuals were
not significantly different among three ELISA assays supporting
that each ELISA assay had comparable results. A total of
five calibrators were used except blank, and the blank OD
(optical density) value was subtracted from each OD value,
and then concentration was calculated by calibration curve.
The lowest concentration the method could determine was 52
pg/mL. The coefficient of variation for netrin-1 was <10%
and <12% in the intra-assay and inter-assay, respectively.
The details of the ELISA assay data are available in the
Supplementary Table S1.
Statistical Analysis
All continuous variables are presented as means ± standard
deviations (SDs), and categorical variables are expressed as n (%).
Parametric differences were compared using analysis of variance
(ANOVA) tests for continuous variables and chi-square tests for
categorical variables and, as appropriate, by post-hoc Bonferroni
tests. To examine the relationship between serum netrin-1 levels
TABLE 1 | Characteristics of the study subjects (n = 218).
Variables Normal
(n = 41)
IFG
(n = 85)
Type 2 diabetes
(n = 92)
P-value
Age (years) 40.9 ± 14.5*** 56.0 ± 9.6 52.6 ± 13.4### <0.001
Female sex 24 (58.5) 49 (57.6) 40 (43.5) 0.107
Current alcohol drinker 21 (4.9) 22 (25.9) 35 (38.0) <0.001
Current smoker 1 (2.4) 10 (11.8) 13 (14.11) 0.133
SBP (mmHg) 124.2 ± 16.8 125.0 ± 12.7 127.6 ± 13.1 0.407
DBP (mmHg) 75.4 ± 10.7 76.7 ± 10.4 79.2 ± 11.2 0.281
BMI (kg/m2) 22.6 ± 3.3** 25.1 ± 3.5 26.3 ± 3.5### <0.001
Statin use 5 (12.2) 18 (21.2) 23 (25.0) 0.247
Fasting glucose (mg/dL) 90.5 ± 6.2 108.6 ± 7.8∧∧∧ 169.7 ± 63.2### <0.001
2-h postprandial glucose (mg/dL)§ 119.1 ± 23.9 138.5 ± 32.1∧∧∧ 238.7 ± 87.4### <0.001
HbA1c (%) 5.3 ± 0.3 5.9 ± 0.2
∧∧∧ 6.8 ± 1.9### <0.001
Glycated albumin (%) 13.2 ± 1.3 14.5 ± 1.5∧∧∧ 21.6 ± 7.2## <0.001
Fasting insulin (µU/mL) 6.2 ± 2.7 8.1 ± 4.5 10.7 ± 9.0## <0.001
Fasting C-peptide (ng/mL) 1.5 ± 0.5* 2.2 ± 0.7∧ 2.6 ± 1.1### <0.001
HOMA-IR 1.37 ± 0.60 2.17 ± 1.24∧∧∧ 4.90 ± 6.13### <0.001
HOMA-β 91.8 ± 76.3* 66.9 ± 39.0∧∧ 42.2 ± 31.3### <0.001
AST (U/L) 19.5 ± 4.9 22.3 ± 9.4∧ 27.9 ± 19.4## <0.001
ALT (U/L) 16.3 ± 6.5 24.5 ± 20.2∧∧ 34.3 ± 26.5### <0.001
Creatinine (mg/dL) 0.76 ± 0.13 0.75 ± 0.17 0.76 ± 0.18 0.943
eGFR (ml/min/1.73m2 ) 102.3 ± 16.8** 91.1 ± 16.7 93.3 ± 19.8# 0.003
Total cholesterol (mg/dL) 190.1 ± 37.0 198.8 ± 43.2 196.3 ± 48.0 0.495
Triglycerides (mg/dL) 103.3 ± 68.7 138.6 ± 70.1∧ 199.3 ± 215.4## 0.001
HDL cholesterol (mg/dL) 56.0 ± 12.7* 51.0 ± 11.1∧∧ 45.1 ± 8.9### <0.001
LDL cholesterol (mg/dL) 114.0 ± 35.2 120.8 ± 39.3 112.7 ± 39.2 0.374
CRP (mg/L) 0.43 ± 0.29 1.02 ± 0.91 1.15 ± 0.86# <0.001
Data are expressed as mean ± standard deviation of the mean or n (%).
*P < 0.05; **P < 0.01; ***P < 0.001 between normal and IFG.
∧P < 0.05; ∧∧P < 0.01; ∧∧∧P < 0.001 between IFG and type 2 diabetes.
#P < 0.05; ##P < 0.01; ###P < 0.001 between normal and type 2 diabetes.
§Levels of postprandial glucose were measured in 17.1% (n = 7), 68.2% (n = 58), and 88.0% (n = 81) in individuals with normal, IFG, and type 2 diabetes, respectively.
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HOMA-β, Homeostasis model
assessment of pancreatic beta cell; HOMA-IR, Homeostasis model assessment of insulin resistance; IFG, impaired fasting glucose; LDL, low density lipoprotein; SBP, systolic blood
pressure.
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and clinical and laboratory parameters, Spearman correlation
analyses were conducted. For multivariable-adjusted regression
analyses, model 1 was adjusted for age, sex, and BMI; model 2
was further adjusted for HbA1c, ALT, HDL cholesterol, eGFR,
and the use of statins; and model 3 was further adjusted for
HOMA-IR. Variables including HbA1c, ALT, HDL cholesterol,
eGFR, andHOMA-IRwere log-transformed in themultivariable-
adjusted regression due to the skewed value distributions. All
covariates in the multivariate models had a variance inflation
factor (VIF) <5.0, which was considered adequate to avoid
relevant multicollinearity. In addition, to evaluate the viability of
serum netrin-1 levels to predict IFG or type 2 diabetes, receiver-
operating characteristic (ROC) curves and areas under the ROC
curves (AUCs) were determined. A P value<0.05 was considered
statistically significant. Statistical analyses were performed using
SPSS version 20.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
Baseline Characteristics of the Study
Population
Baseline characteristics of study subjects according to glycemic
status are shown in Table 1. Among a total of 218 subjects (41
normal controls, 85 subjects with IFG, and 92 subjects with type
2 diabetes), the mean age was 51.7 ± 13.4 years, 51.7% were
women, and themean BMIwas 25.2± 3.7 kg/m2. Comparedwith
normal controls, subjects with IFG or type 2 diabetes were more
likely to be male, obese, and to consume more alcohol. Fasting
and 2-h postprandial glucose and insulin, HbA1c, HOMA-IR,
triglycerides, ALT and C-reactive protein (CRP) concentrations
were significantly increased in subjects with IFG or type 2
diabetes compared to normal subjects (all Ps< 0.05). In contrast,
the levels of HDL cholesterol were markedly lower in individuals
with IFG or type 2 diabetes, compared to normal subjects
(P < 0.005).
Serum Netrin-1 Levels in Subjects With
Normal, IFG, or Type 2 Diabetes
As shown in Figure 1, compared to normal controls mean serum
netrin-1 levels were significantly higher in subjects with type 2
diabetes or IFG (441.0 pg/mL, 436.6 pg/mL and 275.9 pg/mL,
respectively; P for trend <0.001). Furthermore, Figure 2 shows
the ROC curve of serum netrin-1 levels to predict IFG or type 2
diabetes. The AUC was 0.784 (95% CI= 0.693–0.875; P< 0.001).
The use of a cutoff value of 324.9 pg/mL for serum netrin-1 was
associated with the highest value to predict IFG or type 2 diabetes
with a sensitivity and specificity of 80.2% and 73.2%, respectively.
Relationship Between Serum Netrin-1
Levels and Glycometabolic Parameters
To evaluate the association between serum netrin-1 levels
and various clinical and glycometabolic parameters, Spearman
correlation analysis was performed (Table 2). Serum netrin-1
levels had strongly positive correlations with age (r = 0.473,
P < 0.001), male gender (r = 0.213, P = 0.002), and statin use
(r = 0.202, P = 0.003). HbA1c (r = 0.292, P < 0.001), fasting
FIGURE 1 | Comparison of serum netrin concentrations according to
glycemic status. Each horizontal line indicates the mean with 95% confidence
interval. IFG, impaired fasting glucose.
FIGURE 2 | A ROC curve with serum netrin concentrations for the prediction
of IFG or type 2 diabetes. IFG, impaired fasting glucose; ROC, receiver
operating characteristic.
glucose (r = 0.243, P < 0.001), insulin (r = 0.149, P = 0.049),
C-peptide (r = 0.258, P = 0.002), HOMA-IR (r = 0.214,
P = 0.004), AST (r = 0.223, P = 0.001), and ALT (r = 0.142,
P = 0.038) values were also significantly associated with serum
netrin-1 levels. Meanwhile, statistically inverse correlations were
found between netrin-1 and HDL cholesterol (r = −0.229,
P = 0.001) and eGFR (r = −0.468, P < 0.001). Multivariable-
adjusted regression analyses were conducted to investigate the
independent association between serum netrin-1 level and IFG or
type 2 diabetes (Table 3). After adjusting for sex, age, BMI, fasting
Frontiers in Endocrinology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 691
Yim et al. Relationship Between Netrin-1 and T2DM
TABLE 2 | Correlation between serum netrin-1 concentration and glycometabolic
parameters.
Variables R P-value
Age (years) 0.473 <0.001
Female sex −0.213 0.002
Current alcohol drinker 0.118 0.083
Current smoker −0.018 0.792
SBP (mmHg) 0.039 0.611
DBP (mmHg) 0.018 0.809
BMI (kg/m2) 0.125 0.078
Statin use 0.202 0.003
Fasting glucose (mg/dL) 0.243 <0.001
2-h postprandial glucose (mg/dL) 0.046 0.579
HbA1c (%) 0.292 <0.001
Glycated albumin (%) 0.004 0.970
Fasting insulin (µU/mL) 0.149 0.049
Fasting C-peptide (ng/mL) 0.258 0.002
HOMA-IR 0.214 0.004
HOMA-β −0.113 0.135
AST (U/L) 0.223 0.001
ALT (U/L) 0.142 0.038
Creatinine (mg/dL) 0.256 <0.001
eGFR (ml/min/1.73m2 ) −0.468 <0.001
Total cholesterol (mg/dL) −0.009 0.896
Triglycerides (mg/dL) 0.128 0.065
HDL cholesterol (mg/dL) −0.229 0.001
LDL cholesterol (mg/dL) 0.074 0.286
CRP (mg/L) 0.234 0.059
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; HDL, high density lipoprotein; HOMA-β, Homeostasis
model assessment of pancreatic beta cell; HOMA-IR, Homeostasis model assessment of
insulin resistance; LDL, low density lipoprotein; SBP, systolic blood pressure.
plasma glucose, HbA1c, ALT, HDL cholesterol, eGFR, and statin
use, IFG or type 2 diabetes was independently associated with
serum netrin-1 levels (standardized [STD] β = 0.405, P < 0.001;
Model 2). The significant independent association persisted after
further adjustment for HOMA-IR (STD β = 0.425, P = 0.008;
Model 3).
DISCUSSION
The present study demonstrates, for the first time, that serum
netrin-1 level may serve as a sensitive and early indicator of
the development of IFG and type 2 diabetes. Serum netrin-1
concentrations were significantly higher in individuals with IFG
or type 2 diabetes, and serum netrin-1 level was significantly
positively correlated with fasting glucose, HbA1c, HOMA-IR,
AST, and ALT. Serum netrin-1 was also independently associated
with IFG or type 2 diabetes after adjusting for covariates and
potential confounders. Moreover, the AUC to predict IFG and
type 2 diabetes was 0.784.
Netrin-1 belongs to the laminin-related proteins of axon-
guidance and has been reported to play diverse roles through
its two classic receptor families, such as deleted in colorectal
cancer (DCC) subfamily (e.g., DCC and Neogenin) and
uncoordinated 5 (UNC5) subfamily (e.g., UNC5A-UNC5D),
expressed by the target cells (8). Anti-inflammatory actions of
netrin-1 were reported as inhibition of migration of leukocytes
and protection from vascular inflammation, peritonitis,
and pancreatitis through UNC5B receptor (10, 17, 31).
Urinary netrin-1 was elevated in patients with acute kidney
injury after cardiac surgery and was suggested to be an
early predictive biomarker of acute kidney injury before the
rise of serum creatinine (32). In addition, urinary netrin-
1 was elevated early in the time course of rat and human
diabetes (33, 34). However, the purinergic signaling events
by netrin-1 during renal damage demonstrated a protective
role of endogenous netrin-1 in ameliorating disease activity
(35). Overexpression of netrin-1 in kidney proximal tubule
suppressed inflammation and albuminuria through suppression
of diabetes-induced cyclooxygenase-2 (COX-2) expression and
prostaglandin E2 (PGE2) production by inhibiting nuclear
factor kappa B (NF-kB) activation (36). Netrin-1 suppressed
Th1/Th2/Th17 cytokines (e.g., IL-6, IFN-γ, and TNF-α) and
reduced inflammation of renal perfusion injury through
UNC5B receptor (37). Recent studies revealed that netrin-1
interacted with the adenosine 2B receptor (A2BAR) expressed
on polymorphonuclear neutrophils (PMNs) to control local
inflammation during hypoxia and promoted liver repair and
regeneration (14, 16, 38).
Previously, Ay and colleagues reported that serum netrin-
1 levels were raised in patients with diabetes whose mean
HbA1c level was 8.1% compared to non-diabetic patients (39).
Also, there was a strong positive correlation between plasma
netrin-1 level and HbA1c, and a significant negative correlation
between eGFR, but the study sample was relatively small and
a comparative group (such as pre-diabetes) was not included.
In the present study, serum netrin-1 was significantly elevated
in individuals with IFG or type 2 diabetes compared to normal
controls, which is probably attributable to a compensatory
response to IFG or type 2 diabetes. Although mean HbA1c
values were 6.8% in newly-diagnosed drug-naïve patients with
type 2 diabetes and 5.9% in individuals with IFG, we found
grade-dependent levels of serum netrin-1 according to group,
suggesting netrin-1 may be a sensitive indicator for IFG or
early type 2 diabetes. In addition, serum netrin-1 levels were
significantly positively correlated with fasting glucose, HbA1c,
and HOMA-IR whereas they showed a significant negative
correlation with eGFR and HDL cholesterol. In a previous
report, obese individuals (mean BMI 38.6 kg/m2) showed lower
circulating netrin-1 than lean (mean BMI 18.2 kg/m2), whereas,
serum netrin-1 levels were similar in HFD-fed and chow-fed
mice (40). However, BMI was not significantly related with
levels of serum netrin-1 in our study (mean BMI 25.2 kg/m2)
and another study (mean BMI about 24 kg/m2) (41). Liu
and colleagues showed that in patients with newly diagnosed
type 2 diabetes, netrin-1 levels were significantly lower than
in normal controls. There was a negative association between
levels of circulating netrin-1 and fasting and postprandial
blood glucose, HbA1c, triglycerides, and HOMA-IR which were
different from our results (41). These might be explained
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TABLE 3 | Multivariable-adjusted regression analysis of the correlation between serum netrin-1 levels and IFG or type 2 diabetes (n = 218).
Model 1 Model 2 Model 3
R2 0.326 R2 0.405 R2 0.425
STD β P-value STD β P-value STD β P-value
IFG or Type 2 Diabetes 0.266 <0.001 0.293 <0.001 0.251 0.008
Sex −0.209 0.001 −1.654 0.100 −0.136 0.114
Age 0.394 <0.001 0.264 0.002 0.347 0.001
BMI −0.028 0.654 0.005 0.949 −0.044 0.629
HbA1c – – −0.006 0.938 −0.055 0.523
ALT – – −0.028 0.715 −0.079 0.351
HDL cholesterol – – −0.149 0.034 −0.103 0.176
statin user – – 0.061 0.338 0.032 0.642
eGFR – – −0.165 0.063 −0.113 0.261
HOMA-IR – – – – 0.223 0.026
Log-transformation was used for variables (HbA1c, ALT, HDL cholesterol, eGFR, and HOMA-IR).
ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HOMA-IR, Homeostasis model assessment of insulin
resistance; LDL, low density lipoprotein; STD, standardized.
by distinct characteristics of study population. We measured
circulating levels of netrin-1 and other laboratory parameters at
the time of diagnosis of type 2 diabetes, showing mean values of
HbA1c 6.8% and HOMA-IR 4.90. However, Lui et al. recruited
patients who had been diagnosed with type 2 diabetes within
6 months, having mean values of HbA1c 8.5% and HOMA-IR
1.13, indicating more hyperglycemic but not insulin resistant
phenotypes. Furthermore, different commercial netrin-1 ELISA
kits can affect this inconsistent finding. In the previous report,
mean circulating levels of netrin-1 were 1.77 pg/mL in normal
controls and 0.96 pg/mL in patients with type 2 diabetes, but
275.9 pg/mL in normal controls and 441.0 pg/mL in patients
with type 2 diabetes in our study. Similar to our findings,
other reports observed that mean values of serum netrin-1
levels were about 490 pg/mL in obese individuals (40, 42). In
diabetic nephropathy mice model, the mean level of serum
netrin-1 was about 100 pg/mL (35). Different conditions of
study populations, sampling, ELISA kits, and techniques for
measuring netrin-1 may contribute to the discrepancy in results
and these should be considered when interpreting the data.
Further research with a larger sample size may be needed to
improve replicability. The role of netrin-1 is also implicated
in pancreatic morphogenesis, tissue remodeling, and migration
of pancreatic epithelial cells, including duct-cell and fetal islet
cell (43, 44). Recently, Gao et al. showed a direct stimulatory
effect of netrin-1 on insulin secretion in isolated mouse islets by
promoting beta-cell calcium ion influx, and cyclic adenosine 5’-
monophosphate (cAMP) production (45). In the previous study,
improvement of beta-cell function, demonstrated as increased
islet insulin content and plasma insulin levels, normalized
plasma glucagon levels, and enhanced islet vascularization,
were shown in high fat diet/streptozotocin-induced diabetic
mice after netrin-1 administration (45). In addition, netrin-
1-treated diabetic mice presented a substantial reduction in
macrophage infiltration in pancreatic islets and a decrease
in circulating TNF-α levels, showing the anti-inflammatory
action of netrin-1 in diabetes. In diabetic mice, expression
of netrin-1 was decreased in the aorta but, overexpression of
netrin-1 prevented from diabetes-induced vascular damage and
attenuated high glucose-induced oxidative stress (46). However,
there is no longitudinal study of changes in netrin-1 levels
during the development of diabetes and insulin resistance, and
the role of netrin-1 in the pathophysiology of type 2 diabetes
is unclear. Taken together, a possible beneficial compensatory
response of netrin-1 to the changes that happen early in the
time course of diabetes needs to be studied. This perspective
of netrin-1 as a modulator of inflammatory response and
regeneration in pancreas, endogenous circulating netrin-1 may
be implicated in the pathophysiologic mechanism of IFG or
type 2 diabetes (25). In contrast, controversies from different
aspects of netrin-1 applied to various sites. High fat diet-fed obese
mice showed higher expression of netrin-1 and UNC5B mRNA
and macrophage retention in visceral adipose tissue compared
to lean chow-fed mice, and deletion of hematopoietic netrin-
1 facilitated adipose tissue macrophage emigration, reduced
inflammation, and improved insulin resistance in obese mice
(40).
There are several distinguishing aspects of this study. First,
we included drug-naïve, newly-diagnosed patients with type
2 diabetes, minimizing any effect of anti-diabetes medication
on serum netrin-1 concentrations. Second, we identified serum
netrin-1 levels as a possible predictor of both IFG and type
2 diabetes. When we compared netrin-1 levels according to
glycemic status, we found that values were higher in individuals
with IFG and highest in patients with type 2 diabetes compared
with healthy controls. As a potential predictive indicator for
IFG or type 2 diabetes, netrin-1 has the substantial clinical
potential to prevent diabetes or slow its progression. Third, our
sample sizes were larger than in previous reports, increasing
the reliability of results (33, 39–41). Finally, we conducted
multivariable-adjusted regression analyses to investigate the
independent relationships between netrin-1 level and IFG or type
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2 diabetes adjusting for potential confounders, including eGFR
and HOMA-IR.
Notwithstanding, this study has several limitations. Due to
the cross-sectional design of the study, we cannot infer a causal
relationship between an increased netrin-1 concentration and
IFG or early stage of type 2 diabetes. In addition, we could
not measure levels of albuminuria at enrollment, but levels
of eGFR to determine renal function, which was included in
the analyses as a covariate. As levels of postprandial glucose
levels were not measured from all the participants, the diagnosis
of normal controls and subjects with IFG could be affected
and overestimated. Also, various inflammatory cytokines were
not included in the analyses. Moreover, investigation of the
mechanism of action between netrin-1 level and pathogenesis of
IFG and early stage of type 2 diabetes is needed to further our
understanding.
CONCLUSION
In conclusion, we report that elevated serum netrin-1 levels
are significantly associated with IFG or newly diagnosed type 2
diabetes. Further prospective studies are needed to elucidate the
role of netrin-1 in the pathogenesis of type 2 diabetes and expand
its potential for diagnosis and treatment.
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